Vivek Ramaswamy

Vivek Ramaswamy (born August 9, 1985) is an entrepreneur and writer in the biotechnology sector. He is the founder and CEO of the pharmaceutical company Roivant Sciences.

Vivek Ramaswamy
Born (1985-08-09) August 9, 1985
Cincinnati, Ohio, U.S.
Education
Net worth$600 million (April 2017)
Title

As of April 2017, he is worth an estimated $600 million.[1]

Personal life and education

He is the eldest son in his family. His father worked at General Electric and his mother, Geetha Ramaswamy, is a geriatric psychiatrist.[2]

Ramaswamy graduated from St. Xavier High School in Cincinnati in 2003.[3] He graduated summa cum laude from Harvard College with an A.B. in biology. He then received a J.D. from Yale Law School, where his studies were supported by The Paul & Daisy Soros Fellowships for New Americans. [4]

Ramaswamy is married to Apoorva Tewari Ramaswamy, an otolaryngologist. In 2020, after four weeks of maternity leave, she returned to work as a frontline healthcare worker during the COVID-19 pandemic and was infected while treating patients.[5]

Career

Ramaswamy began his career as an investor in the biotechnology sector where he led successful investments in companies developing early-stage therapeutics including the eventual cure for chronic hepatitis C virus.[6] In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009 by the Ewing Marion Kauffman Foundation. Ramaswamy worked at QVT Financial from 2007 to 2014, where he was a partner and co-managed the firm’s biotech portfolio.[7] Ramaswamy appeared on the cover of Forbes magazine in 2015.[8]

Ramaswamy is the founder and CEO of the pharmaceutical company Roivant Sciences. He is also the founder of Axovant Sciences, a clinical-stage pharmaceutical company focusing on treatments for dementia. The initial public offering for Axovant in 2015 raised $360 million.

Ramaswamy served on the Board of Directors of Myovant Sciences, a subsidiary of Roivant Sciences focused on the treatment of women’s health diseases and other endocrine-related disorders. Myovant, formed in April 2016, raised $218 million in its initial public offering, the largest biotech IPO of 2016.[9]

Ramaswamy serves on the Board of Directors of Sumitovant Biopharma. Sumitovant is the result of a $3 billion transaction in 2019 which transferred ownership stakes in five companies in the Roivant family, and includes investigational medicines which generated four successful Phase 3 studies in 2019.[10]

Ramaswamy serves on the Ohio coronavirus task force.[11] He also serves on the Board of Directors of the Foundation for Research on Equal Opportunity, a non-profit, non-partisan think tank that conducts research on expending economic opportunity to those who least have it.[12][13]

Publications
  • The Chimera Question, New York Times, July 16 2007[14]
  • This Pharma Company Stays Innovative by Doing Two Things, Harvard Business Review, March 14 2017[15]
  • The ‘Stakeholders’ vs. the People, Wall Street Journal, February 12 2020[16]

Awards

Forbes 30 Under 30[17]

Crain’s 40 Under 40[18]

Business Insider Young Leaders in Biopharma[19]

References
  1. Kroll, Luisa (April 4, 2017). "America's Richest Entrepreneurs Under 40 2016". Forbes. Retrieved April 5, 2017.
  2. "America's Richest Entrepreneurs Under 40: Vivek Ramaswamy".
  3. Schulte, Becky (July 25, 2015). "July 2015". St. Xavier High School E-news (Mailing list). St. Xavier High School. Retrieved July 26, 2015.
  4. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air".
  5. "Swedish ambassador to the US on her country's path to 'herd immunity' against the coronavirus". Fox News. 2020-05-07. Retrieved 2020-05-21.
  6. Vardi, Nathan. "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air". Forbes. Retrieved 2020-05-13.
  7. "The 29 Year Old Behind The Giant Biotech IPO That Rose By 90% Speaks".
  8. "Forbes September 28, 2015 Vivek Ramaswamy Boy in the Bubble (Magazine: Finance, Business)". IndigoMistBooks. Retrieved 2020-05-13.
  9. "Biggest Biotech IPO Of 2016 Is Launched By 31 Year Old".
  10. "Sumitomo Dainippon and Roivant Close Deal to Form Sumitovant Biopharma". BioSpace. Retrieved 2020-06-26.
  11. "Swedish ambassador to the US on her country's path to 'herd immunity' against the coronavirus". Fox News. 2020-05-07. Retrieved 2020-05-13.
  12. FREOPP (2020-06-12). "More Information About Us". Medium. Retrieved 2020-06-19.
  13. "FREOPP.org". FREOPP.org. Retrieved 2020-06-26.
  14. Ramaswamy, Vivek. "The chimera question". Boston.com. Retrieved 2020-02-27.
  15. Ramaswamy, Vivek; Banta, Ken (2017-03-14). "This Pharma Company Stays Innovative by Doing Two Things". Harvard Business Review. ISSN 0017-8012. Retrieved 2020-02-27.
  16. Ramaswamy, Vivek (2020-02-13). "Opinion | The 'Stakeholders' vs. the People". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-02-27.
  17. "Vivek Ramaswamy, 28". Forbes. Retrieved 2020-03-13.
  18. "40 Under 40 - Vivek Ramaswamy". Crain's New York Business. 2017-03-26. Retrieved 2020-03-13.
  19. Ramsey, Lydia. "Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine". Business Insider. Retrieved 2020-03-13.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.